For research use only. Not for therapeutic Use.
Vatelizumab（Cat No.:I042131）is an investigational monoclonal antibody designed to target and inhibit the integrin α4β7, a receptor involved in the migration of immune cells to the gut. By blocking this receptor, vatelizumab aims to reduce inflammation and immune cell infiltration in the gastrointestinal tract. It is being studied for the treatment of inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. Clinical trials have shown potential in improving symptoms and reducing disease activity in patients with IBD. Ongoing research evaluates its safety, efficacy, and long-term benefits in managing these chronic conditions.
| Catalog Number | I042131 |
| CAS Number | 1238217-55-4 |
| Purity | ≥95% |
